Details of the Drug

General Information of Drug (ID: DMHVBG1)

Drug Name

Naftifine

Synonyms

Naftifin; Naftifina; Naftifinum; Naftifine HCl; Naftifina [INN-Spanish]; Naftifine (INN); Naftifine [INN:BAN]; Naftifinum[INN-Latin]; Naftin (TN); SN 105-843; N-cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride; N-Methyl-N-(1-naphthyl methyl)-3-phenyl-2-propen-1-amine(E), hydrochloride; (2E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine; (E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine; (E)-N-Cinnamyl-N-methyl-1-naphthalinmethylamin; (E)-N-Cinnamyl-N-methyl-1-naphthylmethylamin; (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine

Indication

Disease Entry	ICD 11	Status	REF
Dermatomycosis	EA60	Approved	[1]
Tinea corporis	1F28.Y	Approved	[2]
Tinea cruris	1F28.3	Approved	[2]
Tinea pedis	1F28.2	Investigative	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antifungal Agents

Affected Organisms

Yeast and other fungi

ATC Code

D01AE22: Naftifine

D01AE: Other antifungals for topical use

D01A: ANTIFUNGALS FOR TOPICAL USE

D01: ANTIFUNGALS FOR DERMATOLOGICAL USE

D: DERMATOLOGICALS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

287.4

Logarithm of the Partition Coefficient (xlogp)

5.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 3 days [3]

Chemical Identifiers

Formula: C21H21N
IUPAC Name: (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine
Canonical SMILES: CN(C/C=C/C1=CC=CC=C1)CC2=CC=CC3=CC=CC=C32
InChI: InChI=1S/C21H21N/c1-22(16-8-11-18-9-3-2-4-10-18)17-20-14-7-13-19-12-5-6-15-21(19)20/h2-15H,16-17H2,1H3/b11-8+
InChIKey: OZGNYLLQHRPOBR-DHZHZOJOSA-N

Cross-matching ID

PubChem CID: 47641
ChEBI ID: CHEBI:7451
CAS Number: 65472-88-0
UNII: 4FB1TON47A
DrugBank ID: DB00735
TTD ID: D00HPK

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Squalene monooxygenase (SQLE)	TTE14XG	ERG1_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Dermatomycosis

ICD Disease Classification

EA60

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Squalene monooxygenase (SQLE)	DTT	SQLE	7.14E-03	0.45	2.51

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019356.
2	Naftifine FDA Label
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7.
5	Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.